Mammalian peroxiredoxin V (PrdxV) is a multifunctional protein that protects cells from DNA damage and inhibits stress-induced apoptosis. However, PrdxV is also known to be involved in modulating lipopolysaccharide (LPS)-induced host cell signaling, but its precise role is not fully understood. In this study, we used stably transfected RAW264.7 cells and transiently transfected 293-mTLR4-MD2-CD14 cells expressing wild-type (WT) or mutant (C48S) PrdxV to characterize the function and mechanism of action of PrdxV in LPS-induced immune responses. We found that PrdxV selectively reduces production of interleukin 6 (IL-6) by inhibiting activation of signal transducer and activator of transcription 5 (Stat5) through interaction with Jak2. Notably, this activity of PrdxV was dependent on its catalytic Cys48 residue, but not its peroxidase activity. The binding of to Jak2 effectively inhibited Jak2 phosphorylation, but PrdxV did not act as efficiently as SOCS1 (suppressor of cytokine signaling 1). Our results suggest that PrdxV is a key mediator contributing to the regulation of LPS/TLR4-induced immune responses.
Introduction
Lipopolysaccaride (LPS) is an outer membrane component of gram-negative bacteria and a potent activator of monocytes and macrophages. Macrophages recognize LPS via the Toll-like receptor 4 (TLR4) complex, which is composed of TLR4, myeloid differentiation protein-2 (MD-2), and CD14 [1] , and induces expression of a variety of proinflammatory cytokines, including tumor necrosis factor α (TNF-α), interleukin (IL)-1β, IL-6, IL-12, IL-8, and the interferons (IFNs) [2] .
LPS-induced TLR4 activation is mediated by the adaptor molecules myeloid differentiation primary-response gene 88 (MyD88), MyD88-adaptor-like protein (MAL), TIR (Toll/I-1 receptor) domaincontaining adaptor inducing interferon-β (TRIF), and TRIF-related adaptor molecule (TRAM) [1] . The signal transduced by each adaptor activates downstream signaling molecules that include nuclear factor-κB (NF-κB), mitogen-activated protein kinases (MAPKs), and TRIF-IFN-regulatory factor (IRF3) [3, 4] . In addition, the Jak2-Stat5 pathway is also reportedly activated by LPS/TLR4, though the adaptor molecule for Jak2 has not yet been identified [5] . Activation of these signaling cascades leads to the abundant secretion of the proinflammatory cytokines TNF-α, IL-6, IFN-β, and RANTES [5] [6] [7] [8] .
PrdxV, an atypical 2-Cys peroxiredoxin, is a thiol-dependent peroxidase that reduces hydrogen peroxide (H 2 O 2 ), alkyl hydroperoxides, and peroxynitrite [9, 10] , and exhibits different biochemical and structural features than typical 2-Cys Prdxs [11] . Functionally, PrdxV reacts with a more modest rate constant toward H 2 [12] . In addition, PrdxV is resistant to hyperoxidation by H 2 O 2 [13] . Because the reversible inactivation of Prdxs by hyperoxidation is one of the mechanisms regulated by H 2 O 2 -mediated signaling [14, 15] , PrdxV would appear to be inadequate as a redox sensor. Moreover, PrdxV exhibits broad subcellular localization, being present in mitochondria, peroxisomes, the nucleus, and the cytosol [16] [17] [18] . These characteristics may explain why PrdxV is involved in specific functions and mechanisms that do not involve other Prdxs that are more reactive with H 2 O 2 .
From the time of its discovery, PrdxV has consistently been reported to be involved in inflammation. For example, levels of PrdxV mRNA are reportedly increased in the lungs of rats during acute inflammation induced by LPS [19] . Similarly, bacterial inflammation in mice leads to increases in pulmonary PrdxV [20] . PrdxV is also increased during virus-induced inflammation, and appears to exert a protective effect against oxidative stress in pulmonary epithelial cells [21] . One recent study has shown that PrdxV is up-regulated in LPS-stimulated primary macrophages via a TRIF-dependent, MyD88-independent signaling pathway [22] . In addition, up-regulation of PrdxV significantly inhibits LPS-stimulated macrophage cells through blockade of the MAPKs p38 and JNK [22] . Most recently, microglial PrdxV was shown to be induced to modulate the balance between proinflammatory and anti-inflammatory signals [23] . However, the regulation of inflammatory cytokines in response to LPS-mediated induction of PrdxV has not been well studied.
In the present study, we observed that cytosolic PrdxV was selectively induced in LPS-stimulated macrophages. Interestingly, production of IL-6, but not other cytokines (TNF-α, IFN-β, and RANTES), was reduced in Raw264.7 cells overexpressing PrdxV (PrdxV   WT   ) . In addition, LPS-induced phosphorylation of Jak2, and subsequently Stat5, was significantly impaired in PrdxV WT cells, and the observed effects were blocked by mutation of the catalytic Cys48 residue in PrdxV. Likewise, the binding of PrdxV to Jak2 was also Cys48-dependent. Our findings suggest that PrdxV contributes to the regulation of LPS-induced IL-6 production via a PrdxV-Jak2 pathway that is independent of PrdxV′s peroxidase activity.
Materials and methods

Cell culture
Thioglycollate-induced peritoneal macrophages from C57BL/6J mice and mouse Raw264.7 cells (ATCC, TIB-71) were cultured in complete medium (DMEM supplemented with 10% fetal bovine serum, 50 U/ml penicillin, and 50 μg/ml streptomycin) at 37 1C under a humidified 5% CO 2 atmosphere. Stably transfected RAW264.7 cells ectopically expressing the indicated constructs (PrdxV ) were maintained in complete medium containing 500 mg/ml of G418. 293-mTLR4-MD2-CD14 cells (InvivoGen, San Diego, USA) were maintained in growth medium (DMEM supplemented with 10% FBS, 50 U/ml penicillin, 50 μg/ml streptomycin, 100 μg/ml normocin) containing selective antibiotics (10 μg/ml blasticidin and 50 μg/ml HygroGold). The protocols for collection of peritoneal macrophages from mice were reviewed and approved by the Animal Care Regulations (ACR) Committee of Chonnam National University (Accession Number: CNU IACUC-YB-2008-1).
Reagents and antibodies
Escherichia coli (0111:B4) LPS, N-acetyl-L-cysteine (NAC), and anti-HA agarose conjugate clone HA-7 were purchased from SigmaAldrich. Agarose-conjugated anti-GFP was from MBL. 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H 2 DCFDA) was from Molecular Probes (Invitrogen, CA, USA). Antibodies against Jak2, Stat5, phospho-Jak2, phospho-Stat5, phospho-ERK, phospho-JNK, phospho-c-Jun, phospho-p38, Flag, c-Myc, HA, phosphor-NF-κB p65, and IκBα were all from Cell Signaling Technology (Danvers, MA, USA). Specific antibodies against PrdxI-VI were obtained from the Lab Frontier Life Science Institute (Seoul, Korea). An antibody against SOCS1 was purchased from Abnova Corporation (Taipei, Taiwan), and an antibody against EGFP was from Abcam Corporation.
Plasmid construction
For stable expression of PrdxV in mouse Raw264.7 cells, mouse PrdxV cDNA without the signal sequence was amplified by PCR using primers containing the MluI and XhoI restriction sites. The amplified PCR products were inserted into the pCR3.1 vector, which was modified by insertion of a matrix attachment region (MAR) to induce stable expression, and by substitution of the chicken β-actin/rabbit β-globin hybrid promoter (AG) by the cytomegalovirus immediate early promoter (CMV-IE) from pCAGGS. Substitution of Cys48 in the active site of PrdxV with Ser (C48S) was accomplished through standard PCR-mediated site-directed mutagenesis, after which the mutant was subcloned into the same expression vector used for wildtype (WT) PrdxV. For transient expression in 293-mTLR4-MD2-CD14 cells, mouse WT PrdxV cDNA or a cysteine mutant (C48S, C73S, C152S, or C48/152S) was amplified by PCR using primers containing EcoRI and BglII sites from mouse PrdxV/pCR3.1 constructs as a template. The PCR products were then inserted into pCMV-HA vector (Clontech Laboratories, CA, USA). Mouse Jak2 was amplified by PCR using mouse Jak2/ pEF-BOS plasmid [24] , which was a gift from Dr. Kwang-Hyun Baek (Pochon CHA University, Korea), as a template. The PCR products were cloned into the ScaI and SalI sites in pEGFP-C3 vector (Clontech). Myctagged mouse Stat5b [25] and Flag-tagged Socs1 [26] were gifts from Dr. Jane Visvader (The Walter and Eliza Hall Institute of Medical Research, Australia) and Dr. Dong-Soo Im (KRIBB, Korea), respectively. Plasmid DNA constructs were transfected into mouse RAW264.7 cells and 293-mTLR4-MD2-CD14 cells using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) for stable expression and transient expression, respectively.
Preparation of stable cell lines
To establish Raw 264.7 cell lines overexpressing PrdxV, the cells were seeded into six-well plates at 0.5 Â 10 6 cells per well. They were then transfected with 2 μg of PrdxV Mock , PrdxV WT , or PrdxV C48S DNA using 6 μl of Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) in antibiotic-free DMEM. Beginning 1 day after transfection, transfectants were selected in DMEM containing 500 μg/ml G418, which was refreshed every 2 days for 2 weeks. Colonies surviving in the selection medium were collected and plated in 24-well plates. Cells stably overexpressing PrdxV were identified by immunoblotting with anti-PrdxV and anti-β-actin antibodies or by genomic PCR analysis using primers 5′-GAAGAACTCGTCAAGAAGGC-3′ (forward) and 5′-GATGGATTGCACGCAGGTTC-3′ (reverse), which contain a neomycin-specific sequence. β-Actin served as a loading control.
Cell fractionation
To determine the levels of mitochondrial and cytosolic PrdxV induced by LPS stimulation, 0.5 Â 10 6 RAW264.7 cells were treated with 1 mg/ml LPS for 3 h. The cells were then washed with prechilled PBS and lysed in cytosolic lysis buffer (10 mM Tris-HCl [pH 7.5], 0.3 M sucrose, 10 μM aprotinin A, 10 μM pepstatin, 10 μM leupeptin, 1 mM PMSF). The resultant cell lysates were homogenized on ice using homogenizer, after which the homogenates were spun at 10,000g for 60 min at 4 1C. The resultant supernatant was used as the cytosolic fraction, and insoluble pellet, including the mitochondria, was dissolved in mitochondria lysis buffer (10 mM Tris-HCl, pH 7.5, 1% Triton X-100, 150 mM NaCl, 10 μM aprotinin A, 10 μM pepstatin, 10 μM leupeptin, 1 mM PMSF). The lysate was then spun at 10,000 g for 30 min at 4 1C, and the supernatant was used as a mitochondrial fraction.
Enzyme-linked immunosorbent assay
RAW264.7 cells were seeded into 6-well plates at 0.5 Â 10 6 or 1 Â 10 6 cells per well. After 1 day, the cells were treated with complete medium containing 1 μg/ml LPS, as indicated in the figures. Samples of culture medium were then collected for ELISA analysis. The collected samples were centrifuged at 13,200 rpm for 10 min, after which the supernatants were assayed for IL-6 and TNF-α using using two commercial products: a Quantikine immunoassay kit (R&D Systems, Minneapolis, MN, USA) and an ELISA MAX Deluxe SET kit (BioLegend, San Diego, CA, USA). The levels of IFN-β and RANTES were assayed using a Quantikine immunoassay kit (R&D Systems, Minneapolis, MN, USA).
Real-time PCR
For real-time PCR, total RNA was extracted from cells using QIAzol lysis reagent (Qiagen Science, Maryland, USA), after which cDNA was reverse transcribed from 1-μg samples of total RNA using Prime Script RT reagent (TaKaRa, Shiga, Japan) with oligo-dT and random hexamer. Real-time PCR (50 1C, 2 min; 95 1C, 10 min; 50 cycles of 95 1C, 15 s and 60 1C, 1 min) was performed using SYBR Premix EX Taq (TaKaRa, Shiga, Japan) and an ABI Prism 7300 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). The primer sequences used for realtime PCR were as follows: for GAPDH, 5′-TGTGTCCTCGTGGATCTGA-3′ (F) and 5′-GATGCCTGCTTCACCACCTT-3′ (R); for IL-6, 5′-CTC GGCA-AACCTAGTGAGTTA-3′ (F) and 5′ -ACACACGGATATATTTTCTGACCA-CAGT-3′ (R); for TNF-α, 5′ -TCTGTCTCAGAATGAGGCTGGAT-3′ (F) and 5′-GCATTGCACC TCAGGGAAGA-3′ (R); for IFN-β, 5′-GAGCTATTACTG-GAGGGTGCAAA-3′ (F) and 5′-ATCTCTGCTCGGACCACCAT-3′ (R); for RANTES, 5′-AGCTAGGATAGAGGGTTTCT TGATTCT-3′ (F) and 5′-CCCCAAGCTGGCTAGGACTA-3′ (R); for G-CSF, 5′-GGTGTC CTGGCCATT TCGTA-3′ (F) and 5′-AAGGGCTTTCTGCTCAGGTCTA-3′ (R); and for PrdxV, 5′TTATTGGATGATTCTTTGGTGTCTCT-3′ (F) and 5′-CCTTCAC-TATGCCGT TGTCTATCAC-3′ (R).
Measurement of intracellular ROS
Levels of intracellular reactive oxygen species (ROS) were assessed using 5,6-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate (Invitrogen). RAW264.7 (1.0 Â 10 6 ) cells were incubated with 1 mg/ ml LPS in phenol red-free complete medium for 12 h at 37 1C under a humidified 5% CO 2 atmosphere, after which they were washed with Hank′s buffered salt solution (HBSS). The cells were then harvested using Cell Dissociation Solution (Sigma-Aldrich, Louis, MO, USA), washed once with HBSS, and incubated with 4 μM CM-H 2 DCFH-DA (Invitrogen, Carlsbad, CA, USA) for 20 min at 37 1C. Thereafter, the cells were washed with serum-free, phenol red-free medium and suspended with phenol red-free medium. Finally, the cells were analyzed using flow cytometry to quantify the fluorescent oxidized DCFH (Cytomics FC500, Beckman Coulter, Fullerton, CA, USA).
Immunoprecipitation assay
One day prior to transfection, 293-mTLR4-MD2-CD14 cells were seeded into 60-mm dishes at 1 Â 10 6 cells per dish. The cells were then cotransfected with mammalian expression constructs encoding tagged (GFP, Myc and HA, respectively) mouse Jak2 (0.5 μg), Stat5b (0.8 μg), and PrdxV (WT or C48S, C73S, C152S, or C48/152S; 1 μg).
Twenty-four hours after transfection, the cells were incubated for 3 h in the absence or presence of 0.1 μg/ml of LPS and then lysed in 500 μl of cold lysis buffer (20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, 1 mM NaF, 1 mM Na 3 VO 4 , 0.1 mM AEBSF, 1 μg/ml pepstatin, 1 μg/ml aprotinin, 0.5 μg/ml leupeptin, 1 mM PMSF). After centrifugation, samples of the supernatants (250 μg) were separately immunoprecipitated using GFP-agarose beads (prewashed 10 μl of a 50% slurry) or HA-agarose beads (prewashed 10 μl of a 50% slurry) for 12 h at 4 1C. The beads were then washed three times with cold PBS, and the bound protein was recovered by boiling in SDS-PAGE sample buffer. Thereafter, the proteins were immunoprecipitated with GFP-or HA-agarose beads, separated by SDS-PAGE on a 13.5% gel, and immunoblotted with anti-GFP, anti-Myc, and anti-HA antibodies. In a separate protocol, the expression level of each protein used for immunoprecipitation was also determined using the same antibodies.
Western blotting
To detect phosphorylated proteins, cell lysates were prepared in RIPA buffer containing phosphatase and protease inhibitors (50 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM NaF, 1 mM Na 3 VO 4 , 0.1 mM AEBSF, 1 μg/ml pepstatin, 1 μg/ml aprotinin, 0.5 μg/ml leupeptin, 1 mM PMSF). Protein concentrations were determined using BCA protein assays (Pierce, Rockford, IL), after which aliquots of cell extract containing 30 mg or protein were used for immunoblotting analysis.
Statistical analysis
The data were derived from three independent experiments and expressed as means 7 SEM. Standard t tests were used to assess the significance of differences between and among groups. All statistical analyses were performed using SigmaPlot 9.0 software. P values less than 0.05 were considered significant.
Results
Cytosolic PrdxV is up-regulated in macrophages stimulated with LPS
To assess the involvement of Prdxs in the immune response of macrophages to LPS, we first used Western blotting to examine the level of Prdx expression in macrophages following stimulation with 
, were stimulated with 1 mg/ml LPS for the indicated times (0, 3, 6, and 12 h), after which the culture media and cells were harvested and analyzed for IL-6 and TNFα. Cytokine protein levels were measured using ELISAs (B), while cytokine mRNA levels were measured using real-time PCR (C). The data are presented as the means 7 SD of three experiments. *P>0.1; **P o0.05; and ***Po 0.005.
LPS. On LPS stimulation, PrdxV expression time dependently increased in the RAW264.7 mouse macrophage line (Fig. 1A) and in mouse peritoneal macrophages (Fig. 1B) , whereas the expression of other Prdxs was unchanged. Because PrdxV is broadly distributed within cells [11] , we next determined the subcellular localization of the upregulated PrdxV by lysing LPS-treated Raw264.7 cells and separating the lysates into soluble and insoluble fractions. PrdxIII, a Prdx isotype mainly found in mitochondria, was used as a marker of the insoluble fraction. We found that PrdxV was significantly increased only in the soluble fraction after LPS treatment (Fig. 1C) . These results suggest that it is cytosolic PrdxV that is involved in LPS-induced inflammation.
PrdxV regulates LPS-induced IL-6 production
To examine the effects of the up-regulated PrdxV in LPS-treated macrophages, we stably transfected RAW264.7 cells with empty vector (PrdxV Mock ) or a vector encoding mouse WT PrdxV (PrdxV WT ) (Fig. 2) . The transfectants were screened using Western blotting to assess PrdxV levels ( Fig. 2A) or by genomic insertion using genomic PCR (data not shown). Among the stable cell lines, two PrdxV WT clones, PrdxV WT(1) and PrdxV WT(2) , were compared to PrdxV Mock cells.
The levels of other Prdx isotypes, catalase, and GpxI were unaffected in these cells ( Supplementary Fig. S1 ).
After stimulating the cells with LPS, we first analyzed the protein and mRNA levels of proinflammatory cytokines (Fig. 2B and C and Supplementary Fig. S2 ). In PrdxV Mock cells, LPS induced significant time-dependent production of TNF-α, IL-6, RANTES, and IFN-β. Unexpectedly, however, the levels of both IL-6 mRNA and protein were diminished in PrdxV WT cells, although there were no noticeable changes in the production of the other cytokines tested (TNF-α, IFN-β, and RANTES). This suggests that PrdxV is specifically associated with LPS-induced IL-6 regulation in macrophages.
PrdxV modulates LPS-induced IL-6 production in a catalytic cysteine (Cys48)-dependent manner ROS are known to act as proinflammatory mediators in LPSstimulated macrophages. Typically, 2-Cys Prdxs have a high affinity for H 2 O 2 , enabling them to eliminate the intracellular H 2 O 2 generated in response to TNF-α stimulation [27] , so that PrdxII-deficient macrophages showed an enhanced inflammatory response mediated by up-regulation of H 2 O 2 [28] . In addition, recent studies have noted that PrdxV induction is associated with an increase in ROS/NO levels in LPS-stimulated microglial cells, where it appears to act as an antiinflammatory antioxidant [23] . For those reasons, we compared the effects of PrdxV with those of the antioxidant NAC, a glutathione precursor, to determine whether PrdxV′s inhibition of LPS-induced IL-6 production is secondary to an effect on intracellular ROS. Consistent with an earlier report [23] , levels of PrdxV mRNA and protein correlated with the ROS level by NAC treatment (Fig. 3A and Supplementary Fig. S3A ). Furthermore, the reduction in ROS levels elicited by NAC led to reductions in the proinflammatory cytokines IL-6 and TNF-α (Fig. 3B) . We further compared the antioxidant effect of PrdxII and catalase, a known peroxidase enzyme, in LPS-induced proinflammatory cytokine production. Although anti-inflammatory responses of PrdxII and catalase were lesser than those of the NAC, overexpression of PrdxII and catalase was coincidently affected by reduction of IL-6 and TNF-α production by LPS stimulation, like as antiinflammatory effect of NAC ( Supplementary Fig. S3C-E) . In contrast to the effect of NAC, however, overexpression of PrdxV selectively downregulated IL-6 production; it had no effect on other cytokines (Fig. 2) . To then determine whether PrdxV peroxidase activity is required for the enzyme′s negative regulation of IL-6, we established Raw264.7 cells stably expressing a PrdxV mutant in which the catalytic Cys48 was substituted with Ser (PrdxV C48S cells) (Fig. 4A) . In PrdxV WT cells, overexpression of WT PrdxV had no effect on TNF-α levels, whereas IL-6 levels were notably reduced. In PrdxV C48S cells, by contrast, overexpression of the catalytically inactive mutant PrdxV had no effect on IL-6 levels (PrdxV WT vs PrdxV C48S : Po0.005 by 6 h treatment, P o0.05 at 12 h) (Fig. 4C ).
More interestingly, we found no meaningful difference between the LPS-induced ROS levels in PrdxV Mock vs PrdxV WT cells (P ¼0.48) or PrdxV WT vs PrdxV C48S cells (P>0.1) (Fig. 4B) . Taken together, these results imply that the up-regulation of PrdxV negatively regulates IL-6, not ROS, and that the effect on IL-6 is dependent on the catalytic Cys48 residue of PrdxV.
PrdxV modulates LPS-induced Jak2-Stat5 activation
Activation of the NF-κB and MAPK pathways plays an essential role in mediating the response to proinflammatory stimuli [29] . Therefore, to investigate the involvement of these signals in IL-6 regulation by PrdxV, we compared the phosphorylation levels of various signaling molecules in PrdxV Mock and PrdxV WT cells during LPS stimulation (Fig. 5) . The levels of phospho-ERK1/2, -JNK, -c-Jun, and -p38 MAPK were little affected in PrdxV WT cells, as compared to PrdxV Mock cells, suggesting that overexpression of PrdxV was not directly involved in the activation of MAPK signaling (Fig. 5A ). In addition, activation of the NF-κB was assessed based on IκB degradation, the level of phosphorylated NF-κB p65 (Fig. 5A) , and the level of IκBζ induction (Fig. 5B) . Because IL-6 is reportedly required for induction of IκBζ following LPS stimulation [30] , we used real-time PCR to examine the expression level of granulocyte-colony stimulating factor (G-CSF), which is regulated by IκBζ (Fig. 5B) . We found that expression of G-CSF mRNA differed little between PrdxV WT and PrdxV Mock cells. These results
suggest that IL-6 regulation by PrdxV involves a signaling pathway other than the NF-κB and MAPK pathways. In a recent study, LPS was shown to activate the Jak2-Stat5 signaling pathway, which is involved in IL-6 production through sequential phosphorylation of Jak2 and Stat5. [5] . We therefore investigated the activation of Jak2 and Stat5 using specific antibodies against phospho-Jak2 and phospho-Stat5 (Fig. 5C ). In the absence of LPS stimulation, a low basal level of Jak2 phosphorylation (activation) was detected in PrdxV Mock cells. The evoked phosphorylation of Jak2 and Stat5 peaked after 3 h of LPS stimulation. Interestingly, however, LPS-induced phosphorylation of Jak2 and Stat5 was significantly reduced by overexpression of PrdxV WT .
Furthermore, phosphorylation of Jak2 and Stat5 was sustained in cells expressing catalytically inactive PrdxV C48S after LPS stimulation, and total Jak2 and Stat5 levels were also unchanged (Fig. 5C ). SOCS1 plays a key role in the negative regulation of cytokineinduced Jak-Stat pathways [5, 31] . However, our findings showed that PrdxV does not act by influencing SOCS1 expression, as SOCS1 levels did not differ in LPS-treated PrdxV Mock , PrdxV WT , and PrdcV C48S cells (Fig. 5C ). Taken together, these results suggest that
PrdxV selectively modulates Jak2-Stat5 signaling related to IL-6 expression.
PrdxV interacts with Jak2 via catalytic Cys48
We next investigated how Cys48 of PrdxV is involved in the regulation of Jak2-Stat5 signaling, and whether any of the other Cys residues in PrdxV are involved. To explore the mechanism by which PrdxV regulates the Jak2-Stat5 pathway, we performed pull down assays using 293-mTLR4-MD2-CD14 cells, which stably express all three components (mTLR4, MD2, CD14) needed for LPS-mediated TLR4 activation. These cells were cotransfected with WT or a mutant (C48S, C73S, C152S, C48/152S) PrdxV using a HA-tagged vector along with GFP-tagged Jak2 and Myc-tagged Stat5b expression constructs. Interestingly, a specific interaction between PrdxV and Jak2 was detected in the absence or presence of LPS stimulation (0.1 μg/ml LPS, Fig. 6 ), whereas no PrdxV-Stat5 or Jak2-Stat5 interactions were detected under any conditions. Furthermore, WT PrdxV and the C73S and C152S mutants all significantly bound Jak2, whereas the C48S and C48/152S mutants did not. Given these findings, we propose that PrdxV specifically and directly interacts with Jak2 via Cys48 to regulate the Jak2-mediated Stat5 signaling.
Like SOCS1, PrdxV is involved in Jak2-mediated Stat5 regulation
To compare the efficiencies of PrdxV and SOCS1 as negative modulators of Jak2-Stat5 activation, we assessed the effect of PrdxV, alone or with SOCS1, in LPS-treated 293-mTLR MD2-CD14 cells. Consistent with results in Fig. 5C , WT PrdxV substantially reduced levels of phospho-Jak2, though not completely (Fig. 7A) . By contrast, SOCS1 clearly reduced activation of Jak2-Stat5 to baseline levels. In addition, the amount of PrdxV pulled-downed with Jak2 (anti-GFP agarose) and the amount of Jak2 pulleddowned with PrdxV (anti-HA agarose) were both lower when PrdxV and SOCS1 were expressed together than when PrdxV was expressed alone. This suggests that PrdxV and SOCS1 likely compete for binding to Jak2, and that PrdxV is one of a number of negative modulators, including SOC1, exerting effects on the Jak2-Stat5 pathway via interaction with Jak2.
Discussion
In this study, we demonstrated that PrdxV plays an essential role in regulating LPS-induced IL-6 production via modulation of the Jak2-Stat5 signaling pathway (Fig. 8) . LPS stimulation increases intracellular ROS levels, which in turn activate various signaling cascades (e.g., NF-κB, MAPK, and Jak2-Stat5 pathways), , or PrdxV C48S were stimulated with 1 μg/ml of LPS for the indicated times (0, 3, 6, and 12 h), after which levels of activated Jak2 and Stat5 were determined using anti-phosphoJak2 and anti-phospho-Stat5 antibodies. Total protein levels were determined using antibodies against total (T)-Jak2, T-Stat5, SOCS1, and PrdxV. β-Actin served as a loading control.
leading not only to expression of proinflammatory cytokines (e.g., TNF-α and IL-6), but also to up-regulation of PrdxV. However, unlike the effect of the antioxidant NAC, which inhibits all the effects of ROS, PrdxV functions as a specific regulator of Jak2-Stat5 activation. In the proposed mechanism, PrdxV directly interacts with Jak2 via its catalytic Cys48 residue, which inhibits the sequential phosphorylation of Jak2 and Stat5 induced by LPS and, in turn, reduces IL-6 levels. We therefore propose that PrdxV acts as a negative modulator of Jak2 activation through a mechanism involving protein-protein interaction, but not peroxidase activity. That is, PrdxV appears to regulate IL-6 levels by modulating Jak2-mediated Stat5 activation via PrdxV-Jak2 Fig. 6 . Interaction between PrdxV and Jak2. To determine whether there was a direct interaction between PrdxV and Jak2 and/or Stat5, 293-mTLR4-MD2-CD14 cells were cotransfected with Jak2, Stat5b, and PrdxV (WT or a cysteine mutant: C48S, C73S, C152S, or C48/152S) tagged with GFP, Myc, and HA, respectively. After incubating the transfectants with 0.1 μg/ml LPS for 3 h, they were lysed and the lysates were immunoprecipitated, separated by SDS-PAGE (reducing gel), and immunoblotted using anti-GFP, anti-Myc, and anti-HA antibodies. Expression of each protein used for immunoprecipitation was also determined using the same antibodies (lower panel).
-actin P-Jak2 Within macrophages, LPS stimulation generates reactive oxygen species (ROS), which activate Jak2-Stat5 signaling leading to production of IL-6. At the same time, LPS-induced ROS generation also stimulates expression of PrdxV, which acts as an antioxidant. However, the overexpressed PrdxV does not directly reduce LPSstimulated ROS levels. Instead, PrdxV interacts with Jak2 via its catalytic Cys48 residue, which inhibits phosphorylation of Jak2 and, in turn, Stat5, thereby diminishing IL-6 production.
interaction. Consistent with that idea, only cytosolic PrdxV was induced in LPS-treated Raw264.7 cells (Fig. 1C) , and activation of Jak2-Stat5 by LPS is well known to be a cytosolic event.
It was recently suggested that PrdxII is a negative regulator of LPSinduced inflammatory signaling via ROS synthesis [28] . Consistent with that idea, macrophages from PrdxII-deficient mice produce greater amounts of TNF-α and IL-6 following LPS stimulation as a result of hyperactivation of the NF-κB and JNK, ERK and p38 MAPK pathways. Moreover, the effects correlated with elevated intracellular levels of H 2 O 2 in the PrdxII-deficient macrophages. It has also been reported that PrdxV modulates redox-sensitive neuroinflammatory cytokine production [23] . In the present study, however, we observed a specific reduction in LPS-induced IL-6 production in PrdxV WT cells, with no effect on other cytokines ( Fig. 2 and Supplementary Fig. S2 ).
In addition, although the catalytic cysteine of PrdxV, Cys48, is clearly involved in the regulation of IL-6 production via the Jak2-Stat5 pathway (Figs. 4 and 5C ), the ability of PrdxV to affect LPS-induced ROS levels did not differ in PrdxV Mock , PrdxV WT , and PrdxV C48S cells (Fig. 4B) . By contrast, removing ROS using the well-known chemical antioxidant NAC or the well-known peroxidase enzyme PrdxII and catalase nonspecifically inhibited LPS-stimulated proinflammatory cytokine signals (IL-6 or TNF-α) as well as LPS-induced PrdxV induction ( Fig. 3 and Supplementary Fig. S3A and S3C-E). Likewise, LPS-induced Jak2-Stat5 activation (phosphorylation) was reduced by NAC ( Supplementary Fig. S3B ). In other words, PrdxV expressed in response to LPS stimulation does not act as an antioxidant that inhibits all proinflammatory cytokine signaling; instead, it functions specifically to regulate IL-6. It is noteworthy that the serial phosphorylation of Jak2 and Stat5 was affected by the up-regulation of PrdxV. In both stable and transient expression systems, overexpression of PrdxV inhibited the sequential activation of Jak2 and Stat5, leading to IL-6 production ( Fig. 2 and Figs. 5C and 7A ). This suggests that PrdxV is directly involved in the activation of the Jak2-Stat5 pathway. Our findings indicate that exogenously expressed PrdxV interacts with Jak2 in LPS-treated 293-mTLR4-MD2-CD14 cells, and that their interaction is lost when Cys48 of PrdxV is substituted with Ser (Fig. 6) . We therefore hypothesize that PrdxV acts to inhibit IL-6 through Jak2-dependent Stat5 inhibition mediated by proteinprotein interaction.
Canonical and noncanonical activation of Jak2 is regulated by various mechanisms and molecules, including phosphorylation, nitration, pseudokinase domains, adaptor proteins, and reactive oxygen and nitrogen species (ROS/RNS) [32] . Among these, regulation of Jak activity by ROS/RNS remains controversial, in part because activation of Jak2 by ROS is often indirect [33, 34] . For example, indirect activation of Jak2 may result from oxidative inhibition of the active site Cys in protein tyrosine phosphatases, which increases phosphotyrosine levels in Jak2 [35] [36] [37] . GPCRmediated Jak2 activation and angiotensin II-induced Jak2 activation also involves subsequent activation of NADPH oxidase [38, 39] . In vivo, Jak2 is activated in cardiac myocytes by acute oxidative stress, although the precise mechanism is unknown [40, 41] . Inactivation of Jak2 by oxidants has been mainly studied using a biochemical approach. For example, the thiol redox status of Jak2 and Jak3 was recently shown to affect autokinase activity [42] . In particular, the four Cys residues in the catalytic domain (Cys866, Cys917, Cys1094, and Cys1105) are closely involved in maintaining Jak2′s catalytic activity [43] . In addition, oxidative stress was shown to inhibit the secretion of ciliary neurotrophic factor (CNTF), which was mediated by Jak2, in H 2 O 2 -treated nerve cells [44] , and parthenolide-induced oxidative stress inhibits Jak1 activity [45] . In the present study, we showed that the peroxidase activity of PrdxV does not meaningfully affect LPS-induced ROS production in macrophages (Fig. 5B) , though it is a critical for macrophage activation [46] . Instead, we found that Cys48 of PrdxV is involved in the PrdxV-Jak2 interaction (Fig. 6) . The Jak2 domain or residues involved in the interaction remain to be determined.
It has been reported that SOCS1 selectively inhibits LPSinduced IL-6 production by regulating the Jak2-Stat5 signaling pathway [5] . The regulation of Jak2-Stat5 activation by PrdxV was not as efficient as that by SOCS1 in LPS-treated 293-mTLR4-MD2-CD14 cells (Fig. 7B) . Nonetheless, our results clearly indicate that PrdxV specifically and negatively regulates the Jak2-Stat5 pathway to IL-6 production following LPS stimulation. SOCS1 protein contains a kinase inhibitory region (KIR), which is thought to function as a pseudosubstrate; a central Src Homology 2 (SH2) domain; and a conserved C-terminal region, which is referred to as a SOCS box [47] . SOCS1 directly regulates Jak2 activity by binding to the activation loop of the catalytic domain through both its KIR and its SH2 domains. PrdxV does not contain a SH2 domain. Therefore, the structural basis for its interaction with Jak2 likely differs from that of SOCS1 and remains to be characterized.
In summary, we have demonstrated that cytosolic PrdxV plays a key role in negatively regulating LPS-induced IL-6 production through an inhibitory effect on Jak2-Stat5 signaling. PrdxV appears to act by binding to Jak2 via its catalytic Cys48 residue, though it does not involve its peroxidase activity. Although the mechanism by which PrdxV interacts with Jak2 likely differs from SOCS1, our findings suggest that PrdxV is involved in LPS-mediated innate immunity.
